Revenue segments as reported by the company.

Net product sales

Alliance and other revenues

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Marketing, selling and administrative

Research and development

IPRD charge - MyoKardia acquisition

Amortization of acquired intangible assets

Other (income)/ expense, net

Acquired IPRD

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Bristol-Myers

Bristol Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. It offers chemically-synthesized drugs or small molecules and products produced from biological processes called biologics. The company was founded in August 1933 and is headquartered in New York, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Bristol-Myers reports robust 2022 performance and outlines growth strategies

Bristol-Myers Squibb delivered strong financial performance in 2022, with revenue growth and key product successes driving sales to $46 billion.
The company's strategic focus on portfolio expansion, market access enhancement, and operational efficiency positions it for continued growth and value creation.
Challenges around market access, legislative impacts, and expense management require strategic attention, while opportunities in product development and market expansion offer avenues for future growth.

Bristol-Myers reports robust Q1 earnings, eyes growth amid challenges

Bristol-Myers' Q1 2023 performance reflects strong sales growth and a focus on innovation, with significant progress in pipeline development and new product launches.
While facing challenges from generic competition and operational issues, the company is well-positioned to capitalize on industry advancements and strategic opportunities for growth.
By reaffirming guidance, emphasizing strategic alignment, and pursuing new therapies, Bristol-Myers demonstrates resilience and a commitment to long-term success in the pharmaceutical market.

Bristol-Myers reports robust Q2 sales and strategic growth initiatives

Bristol-Myers' Q2 performance showcased strong sales driven by new product growth and key product successes like Opdivo and Reblozyl.
While facing challenges with certain products and revenue guidance changes, the company remains confident in its financial commitments and growth outlook.
Opportunities lie in capacity ramp-up for key products, conversion strategies for patient assistance programs, and upcoming R&D insights.
Overall, Bristol-Myers' performance, strengths, and opportunities position the company for continued growth and success in the pharmaceutical market.

Bristol-Myers reports robust Q3 performance, eyes growth opportunities

Bristol-Myers Squibb's Q3 earnings call highlighted strong performance, strategic initiatives for growth, and confidence in future prospects. Despite challenges in product performance and reimbursement, the company is optimistic about market improvements and growth opportunities. Executives are focused on driving sustainable long-term growth and expanding their product portfolio.

Bristol-Myers reports robust Q4 earnings, eyes growth through strategic initiatives

Bristol-Myers' Q4 2023 showcased strong financial performance, strategic advancements, and a focus on growth drivers like Opdivo and new launches.
Despite challenges in negotiations and market dynamics, Bristol-Myers remains poised for growth through its robust product portfolio and business development strategies.
The company's emphasis on innovation, commercial execution, and clinical progress positions Bristol-Myers for sustained growth and market leadership in the pharmaceutical industry.

Bristol-Myers meets Q1 expectations, focuses on growth opportunities

Bristol-Myers Squibb's Q1 performance met expectations with strong sales growth driven by key brands and strategic acquisitions.
Despite challenges in operating expenses and interest costs impacting income, the focus on efficiency and cost savings remains a priority.
The company's strengths lie in robust sales growth of key brands, promising pipeline advancements, and strategic capital allocation plans.
Opportunities in expanding indications, new trials, and market launches position Bristol-Myers for long-term growth and competitive advantage.

Bristol-Myers reports strong Q2 performance, bullish on pipeline growth

Bristol-Myers (BMY) showcased a robust Q2 performance, emphasizing pipeline advancements and strategic capital allocation for growth and returns.
The company is confident in navigating pricing changes and improving access dynamics for key products, while focusing on transformative medicines and operational excellence.
With a positive outlook for the year, Bristol-Myers is poised to leverage opportunities in oncology, pipeline advancements, and expanding indications for key assets.

Bristol-Myers (BMY) reports strong Q3 sales and pipeline progress

Bristol-Myers Squibb (BMY) showcased robust performance with strong sales growth and positive clinical data for pipeline programs.
The company's strategic strengths lie in operational excellence, capital allocation, and commitment to sustainable growth and innovation.
Challenges include market dynamics, competition in heart failure drugs, and translating clinical data into successful drug programs.
Opportunities abound in the growing heart failure drugs market, upcoming trial data readouts, and continued focus on portfolio growth and operational efficiency.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Bristol Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. It offers small molecules, products produced from biological processes called biologics, and chimeric antigen receptor (CAR-T) cell therapies. The company was founded in August 1933 and is headquartered in Princeton, NJ.

bluebird (BLUE) and partner Bristol Myers clinch an FDA approval for their chimeric antigen receptor T cell immunotherapy Abecma to address relapsed or refractory multiple myeloma.

bluebird (BLUE), Bristol Myers CAR T Cell Therapy Gets FDA Nod

SAN DIEGO, March 30, 2021 /PRNewswire/ -- HUYABIO International (HUYABIO™), the leader in accelerating global development of China's pharmaceutical innovations, today announced that it had entered into a clinical collaboration agreement with Bristol-Myers Squibb Company (NYSE: BMY) to evaluate the combination of HUYABIO's HBI-8000, an epigenetic immunomodifier, and Opdivo® (nivolumab), a PD-1 blocking antibody. The Phase 3 trial is designed to evaluate the safety and efficacy of the combination in subjects with unresectable or metastatic melanoma not previously treated with anti-PD-1 therapy.

Huyabio International Announces Global Clinical Trial Collaboration With Bristol Myers Squibb In Melanoma

NEW YORK--(BUSINESS WIRE)---- $BMY--Bristol Myers Squibb to Host Virtual Investor Event to Discuss AAD VMX Highlights

Bristol Myers Squibb to Host Virtual Investor Event to Discuss AAD VMX Highlights

The U.S. FDA has approved Abecma, a CAR-T (chimeric antigen receptor T cells) cell immunotherapy for the treatment of relapsed multiple myeloma after four or more prior lines of therapy. Abecma was being developed by Bristol Myers Squibb and bluebird bio Inc. CAR-T therapy refers to extraction.

Should You Buy Bristol Myers Squibb Stock At $63?

BJ`s Wholesale Club Holdings Inc

Generac Holdings

Hamilton Lane

XPO Logistics

Amid see-sawing markets, Q.ai's Artificial Intelligence has brought you today's top buys.

Top Stocks To Buy Today As The Markets Make Moves

Air Products and Chemicals

Comcast

Cisco Systems

General Dynamics

Illinois Tool Works

Mastercard

Oracle

Stryker

In this article series, we provide a summary of upcoming ex-dividend dates. We present a summary table with relevant data and key statistics, including the next payout and pay date.

Upcoming Ex-Dividend Dates: March 30-April 12, 2021

Bristol Myers Squibb (NYSE: BMY) looks very attractive at current levels of $63, as it is up only 40% from the levels it was at on March 23, 2020, when broader markets made a bottom due to the spread of Covid-19. This marks an underperformance compared to the S&P which has moved 75%.

Here's Why Bristol Myers Squibb Stock Is Undervalued At $63

PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #Opdivo--European Medicines Agency Validates BMS's Application for Opdivo as Adjuvant Treatment for Patients with Muscle-Invasive Urothelial Carcinoma

European Medicines Agency Validates Bristol Myers Squibb's Application for Opdivo (nivolumab) as Adjuvant Treatment for Patients with Muscle-Invasive Urothelial Carcinoma

The Pharma giant Bristol Myers Squibb has barely generated any shareholder momentum in the past 5 years. However, management's calculated bet to acquire Celgene for $77bn in late-2019 is looking like a better bet with each passing day.

Bristol Myers Squibb's Floundering Days Could Be Behind It - Full Steam Ahead

PRINCETON, N.J., & CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $BMY #BMS--U.S. FDA Approves Bristol Myers Squibb's & bluebird bio's Abecma, the First Anti-BCMA CAR T Cell Therapy for Relapsed and Refractory Multiple Myeloma

U.S. Food and Drug Administration Approves Bristol Myers Squibb's and bluebird bio's Abecma (idecabtagene vicleucel), the First Anti-BCMA CAR T Cell Therapy for Relapsed or Refractory Multiple Myeloma

AbbVie

Amgen

Gilead Sciences

Johnson & Johnson

Eli Lilly

Sanofi

Pharmaceutical stocks with stable, substantial dividends can hold their own in almost any environment, making them ideal for long-term income investors.

7 Big Pharmaceutical Stocks for Bigger Income

Bristol-Myers (BMY) announces encouraging primary results from a study, evaluating a fixed-dose combination of relatlimab and immuno-oncology drug, Opdivo, in metastatic or unresectable melanoma.

Bristol-Myers (BMY) Announces Results From Opdivo Combo Study

Citigroup

Enterprise Products Partners

Intel

MPLX

Prudential Financial

Simon Property Group

SPDR S&P 500 ETF Trust

AT&T

Vanguard Value ETF

Vanguard Growth ETF

W. P. Carey

At the end of 2020, we showcased a list of 10 undervalued income stocks for 2021. Looking back, we see that the performance, on average, has been great so far. In this report, we examine the reasons for that and will look at whether all 10 are still strong buys today.

Top 10 Undervalued Income Stocks For 2021 - Value Beats Growth

PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #Cancer--BMS Announces RELATIVITY-047 Meets Primary Endpoint of Progression-Free Survival

Bristol Myers Squibb Announces RELATIVITY-047, a Trial Evaluating Anti-LAG-3 Antibody Relatlimab and Opdivo (nivolumab) in Patients with Previously Untreated Metastatic or Unresectable Melanoma, Meets Primary Endpoint of Progression-Free Survival

Merck

Pfizer

A look at undervalued pharma stocks offering yields that are at least double that of the S&P 500

3 Undervalued Pharma Stocks for Sleep-Well-at-Night Income

Citizens Financial Group

Marathon Petroleum

PepsiCo

Raytheon Technologies

One of Wall Street's most respected lists of domestic stocks is the Goldman Sachs America's Conviction List.

5 Goldman Sachs Conviction List Stocks to Buy Now That Pay Big Dividends

The FDA accepts Bristol Myers' (BMY) new drug application for mavacamten for treating patients with symptomatic obstructive hypertrophic cardiomyopathy.

Bristol Myers' (BMY) NDA for Mavacamten Accepted by FDA

Medtronic

This article series provides a summary of upcoming ex-dividend dates. We present a summary table with relevant data and key statistics, including the next payout and pay date.

Upcoming Ex-Dividend Dates: March 23-April 5, 2021

BioCryst Pharmaceuticals

Marker Therapeutics Inc

Pacira Pharmaceuticals

ProQR Therapeutics

Rubius Therapeutics Inc

Zealand Pharma

Biotech stocks reversed course in the week ended March 19 amid mixed news flow on data readouts and lackluster broader market performance. Rubius Therapeutics, Inc. (NASDAQ: RUBY) was among the biggest gainers of the week after the biopharma reported positive Phase 1/2 data for its RTX-240 in solid tumors.

FDA Decisions For Pfizer, Eli Lilly And Bluebird Bio, Bristol-Meyers Squibb, Plus New Data And Earnings

The FDA has accepted for review Bristol-Myers Squibb Co's (NYSE: BMY) marketing application for mavacamten for symptomatic obstructive hypertrophic cardiomyopathy. The FDA has assigned a goal date of January 28, 2022.

FDA Accepts Bristol-Myers' Mavacamten Application In Inherited Heart Disease For Review

PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #FDA--U.S. FDA Accepts Bristol Myers Squibb's Application for Mavacamten in Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM)

U.S. Food and Drug Administration (FDA) Accepts Bristol Myers Squibb's Application for Mavacamten in Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM)

General Motors

Verizon

Successful money managers have been piling into these cheap brand-name stocks.

4 Value Stocks Billionaires Can't Stop Buying

Iovance Biotherapeutics

The prospects for several drug makers—and their investors—are likely to be affected as clinical trial results for key medications are reported this year.

Eli Lilly, Bristol-Myers and Iovance Await Important Drug Trial Results

AVEO Pharma

AVEO forges an alliance with Bristol Myers to evaluate Fotivda in combination with Opdivo for RCC.

AVEO Collaborates with Bristol Myers to Conduct Combo Study

News for Bristol-Myers Stock (BMY)